Smothers C Thetford, Woodward John J
Department of Neurosciences, Division of Neuroscience Research, and Center for Drug and Alcohol Programs, Medical University of South Carolina, Charleston, South Carolina 29425, USA.
J Pharmacol Exp Ther. 2007 Aug;322(2):739-48. doi: 10.1124/jpet.107.123836. Epub 2007 May 14.
N-Methyl-D-aspartate (NMDA) receptors are important targets for drugs of abuse such as ethanol, toluene, and ketamine. Ligand-gated ion channels assembled from the NR1 and NR3 subunits have functional and pharmacological properties that are distinct from those of conventional NMDA receptors containing NR2 subunits. In the present study we used voltage-clamp electrophysiology to characterize excitatory glycine-activated receptors assembled from NR1, NR3A, and NR3B subunits expressed in human embryonic kidney (HEK) 293 cells. These glycine-activated receptors were not stimulated by glutamate or kainic acid and were resistant to magnesium block. A wide variety of NMDA receptor antagonists including d-2-amino-5-phosphonovaleric acid, ifenprodil, memantine, (5R,10S)-(+)-5-methyl-10,11-dihydro-5H-dibenzo[a,d]cyclo-hepten-5,10-imine hydrogen maleate (MK-801) or acamprosate did not inhibit glycine-activated NR1/NR3A/NR3B receptors. Likewise, these receptors were not affected by antagonists of inhibitory glycine receptors or glycine transporters. The NMDA receptor glycine site agonist, d-serine, partially activated NR1/NR3A/NR3B receptors, whereas the antagonist, 5,7-dichloro-kynurenic acid, inhibited receptor currents. Conversely, the antagonist, 7-chlorokynurenic acid, and the partial agonist, R-(+)-3-amino-1-hydroxy-2-pyrrolidinone (HA-966), potentiated glycine-stimulated currents of these receptors. NR1/NR3A/NR3B receptor currents were inhibited by 10 to 21% by ethanol and toluene but were relatively insensitive to ketamine. Ethanol inhibition was enhanced in receptors expressing the NR1(L819A) mutant, whereas those containing NR1(F639A) or NR1(M813A) showed no change relative to the wild-type NR1. The results of this study indicate that coexpression of NR1, NR3A, and NR3B subunits in HEK 293 cells results in glycineactivated receptors with novel functional and pharmacological properties.
N-甲基-D-天冬氨酸(NMDA)受体是乙醇、甲苯和氯胺酮等滥用药物的重要作用靶点。由NR1和NR3亚基组装而成的配体门控离子通道具有与含有NR2亚基的传统NMDA受体不同的功能和药理特性。在本研究中,我们使用电压钳电生理学方法来表征在人胚肾(HEK)293细胞中表达的由NR1、NR3A和NR3B亚基组装而成的兴奋性甘氨酸激活受体。这些甘氨酸激活受体不受谷氨酸或 kainic 酸刺激,并且对镁离子阻滞具有抗性。包括d-2-氨基-5-磷酸戊酸、ifenprodil、美金刚、(5R,10S)-(+)-5-甲基-10,11-二氢-5H-二苯并[a,d]环庚烯-5,10-亚胺氢马来酸盐(MK-801)或阿坎酸在内的多种NMDA受体拮抗剂均不抑制甘氨酸激活的NR1/NR3A/NR3B受体。同样,这些受体不受抑制性甘氨酸受体或甘氨酸转运体拮抗剂的影响。NMDA受体甘氨酸位点激动剂d-丝氨酸可部分激活NR1/NR3A/NR3B受体,而拮抗剂5,7-二氯犬尿氨酸可抑制受体电流。相反,拮抗剂7-氯犬尿氨酸和部分激动剂R-(+)-3-氨基-1-羟基-2-吡咯烷酮(HA-966)可增强这些受体的甘氨酸刺激电流。NR1/NR3A/NR3B受体电流被乙醇和甲苯抑制10%至21%,但对氯胺酮相对不敏感。在表达NR1(L819A)突变体的受体中,乙醇抑制作用增强,而含有NR1(F639A)或NR1(M813A)的受体与野生型NR1相比无变化。本研究结果表明,在HEK 293细胞中共表达NR1、NR3A和NR3B亚基可产生具有新型功能和药理特性的甘氨酸激活受体。